Search
Feed aggregator
Intra-Cellular Looks to Raise $500M in Public Offering Following Phase III MDD Win
Intra-Cellular Looks to Raise $500M in Public Offering Following Phase III MDD Win 4/18/2024
Cerevel Gets Phase III Parkinson’s Win on Heels of $8.7B AbbVie Acquisition
Cerevel Gets Phase III Parkinson’s Win on Heels of $8.7B AbbVie Acquisition 4/18/2024
Most Doses of Lilly’s Zepbound and Mounjaro in Short Supply Through Q2: FDA
Most Doses of Lilly’s Zepbound and Mounjaro in Short Supply Through Q2: FDA 4/18/2024
Teva, Alvotech Secure FDA Approval for Stelara Biosimilar with Early 2025 Launch
Teva, Alvotech Secure FDA Approval for Stelara Biosimilar with Early 2025 Launch 4/18/2024
Roche’s Ocrevus Achieves Near-Complete Reduction of Relapse, Lesions in MS
Roche’s Ocrevus Achieves Near-Complete Reduction of Relapse, Lesions in MS 4/18/2024
Bioversity Program Preps Grads for Early-Career Life Science Roles
Bioversity Program Preps Grads for Early-Career Life Science Roles 4/18/2024
How to Deal With Layoff-Related Stress
How to Deal With Layoff-Related Stress 4/18/2024
Career Coach: How to Look Professional in Virtual Meetings
Career Coach: How to Look Professional in Virtual Meetings 4/18/2024
5 Top Companies Hiring Oncology Jobs
5 Top Companies Hiring Oncology Jobs 4/18/2024
Lilly Eyes Zepbound Label Expansion After Clearing Phase III Sleep Apnea Study
Lilly Eyes Zepbound Label Expansion After Clearing Phase III Sleep Apnea Study 4/17/2024
Sage Axes Parkinson’s Program for Dalzanemdor After Phase II Flop
Sage Axes Parkinson’s Program for Dalzanemdor After Phase II Flop 4/17/2024
Amylyx Sheds More Light on Relyvrio’s Late-Stage Trial Failure in ALS
Amylyx Sheds More Light on Relyvrio’s Late-Stage Trial Failure in ALS 4/17/2024
Amylyx at a Crossroads: Can the Company Overcome the Loss of Relyvrio?
Amylyx at a Crossroads: Can the Company Overcome the Loss of Relyvrio? 4/17/2024
Arvinas Strikes Deals With Pfizer, Novartis to Compete in Protein Degrader Space
Arvinas Strikes Deals With Pfizer, Novartis to Compete in Protein Degrader Space 4/17/2024
Top Q1 Series A Investments Highlight VC Rebound in Biopharma
Top Q1 Series A Investments Highlight VC Rebound in Biopharma 4/17/2024
Canaan Secures More Than $100M in New Biopharma Funding, Adds Former Pfizer Executive
Canaan Secures More Than $100M in New Biopharma Funding, Adds Former Pfizer Executive 4/17/2024
Cullinan Targets Autoimmune Market, Nabs $280M in Private Placement
Cullinan Targets Autoimmune Market, Nabs $280M in Private Placement 4/17/2024
GSK Touts Late-Stage Antibiotic Win in Gonorrhea, Long-Term Shingrix Vaccine Data
GSK Touts Late-Stage Antibiotic Win in Gonorrhea, Long-Term Shingrix Vaccine Data 4/17/2024
Arrowhead’s Plozasiran Poised for Dyslipidemia Market, $700M in Sales by 2032: GlobalData
Arrowhead’s Plozasiran Poised for Dyslipidemia Market, $700M in Sales by 2032: GlobalData 4/17/2024
Amylyx and ALS, Continued ADC Excitement, Dire Drug Shortages
Amylyx and ALS, Continued ADC Excitement, Dire Drug Shortages 4/17/2024
World Pharma News
- AI-assisted approach identifies IRS4 as a promising drug target in multiple solid tumors
- Researchers identify natural compound that disarms drug-resistant bacteria
- Scientists discover a new way to make drug-resistant cancer treatable again
- A new drug concept to treat obesity and type 2 diabetes
- Autonomous AI-based drug prescribing rife with potential problems